Organization
Queen's University, Belfast
2 clinical trials
11 abstracts
Clinical trial
A Cross-sectional Study to Measure Cough in Severe AsthmaStatus: Completed, Estimated PCD: 2019-12-30
Clinical trial
Investigation of Biomarker Response to SGLT2 Inhibition Across Various Phenotypes of Heart FailureStatus: Recruiting, Estimated PCD: 2024-09-01
Abstract
Toxicity reporting consistency and subjective minimizing language use in colorectal cancer (CRC) and pancreatic cancer (PaC) clinical trials: A systematic review of phase III randomized controlled trials (RCTs) presented at ASCO between 2012-2022.Org: H. Lee Moffitt Cancer Center and Research Institute, Moffitt Cancer Center and Research Institute, London Health Sciences Centre & Schulich School of Medicine, University of Toronto, Queen's University, Belfast,
Abstract
Impact on turnaround times (TAT) among non-squamous non-small cell lung cancer (NSCLC) patients across three time periods with varying biomarker testing techniques.Org: University of Toronto, Institute of Health Policy, Management, and Evaluation, University Health Network, Queen's University, Belfast, Princess Margaret Cancer Centre,
Abstract
Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.Org: University Health Network, BCCA Vancouver Cancer Centre, The Ottawa Hospital Cancer Centre, Providence Cancer Institute, Queen's University, Belfast,
Abstract
Reversion of RAS mutations in metastatic colorectal cancer in the CCTG CO.26 clinical trial.Org: BC Cancer-Vancouver Centre, Pancreas Centre BC, Canadian Cancer Trials Group, Queen's University, Belfast, Providence Cancer Institute,
Abstract
CCTG HN11: SPECT-CT guided elective contralateral neck treatment (SELECT) for patients with lateralized oropharyngeal cancer—A phase III randomized controlled trial.Org: University Health Network, Canadian Cancer Trials Group, CHUM - Centre Hospitalier de l'Universite de Montreal, Centre Hospitalier Universitaire de Sherbrooke (CRCHUS), University of Toronto,
Abstract
Comparing the time toxicity of cancer treatments in the CCTG LY.12 trial.Org: University of Minnesota Masonic Cancer Center, Minneapolis, MN, Queen's University, Belfast, Princess Margaret - University Health Network, Canadian Cancer Trials Group, NCIC Clinical Trials Group,
Abstract
UK cancer healthcare professionals collaborating with colleagues in low- and middle-income counties: Mapping the extent and nature of partnerships.Org: UK Global Cancer Network, Royal United Hospitals Bath NHS Foundation Trust, University of Warwick, BALCO Medical Center, Aga Khan University Hospital,
Abstract
Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population-based evaluation.Org: London School of Hygiene and Tropical Medicine, Clinical Effectiveness Unit, The Royal College of Surgeons of England, Royal College of Surgeons of England, London School of Hygiene & Tropical Medicine,
Abstract
Accrual of adolescents and young adults (AYA) into cancer clinical trials in Canada.Org: Canadian Cancer Trials Group, University of Calgary, The Children's Hospital of Eastern Ontario, Research Institute of McGill University Health Centre, CancerCare Manitoba,
Abstract
Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: A cost consequence analysis using linked administrative data.Org: Princess Margaret Cancer Centre, Institute for Clinical Evaluative Sciences, University Health Network, Sunnybrook Health Sciences Centre, Odette Cancer Centre,
Abstract
Association of socioeconomic status (SES) with use of specialist palliative care (SPC) among people who died with cancer before and during the COVID-19 pandemic.Org: University Health Network (UHN), University of Toronto, Division of Medical Oncology & Haematology, Princess Margaret Cancer Centre, UHN, Queen's University, Belfast, University of Ottawa,